# Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement

Study · id `cardio:ct-nct03121053` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03121053](<https://clinicaltrials.gov/study/NCT03121053>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03121053

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Valve and congenital heart disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03121053. Randomized; no masking; primary purpose prevention. Start 2016-10 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03121053, source copy `cardio:ctgov-nct03121053-2017-04-19`, retrieved 2026-10-26)
- Start date: 2016-10 (registry gives no type) (ClinicalTrials.gov record NCT03121053, source copy `cardio:ctgov-nct03121053-2017-04-19`, retrieved 2026-10-26)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT03121053, source copy `cardio:ctgov-nct03121053-2017-04-19`, retrieved 2026-10-26)
- Completion: 2019-01 (anticipated) (ClinicalTrials.gov record NCT03121053, source copy `cardio:ctgov-nct03121053-2017-04-19`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT03121053, source copy `cardio:ctgov-nct03121053-2017-04-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03121053-2017-04-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
- Acronym: PANTER
- Condition: Aortic Valve Disease
- Condition: Chronic Kidney Disease
- Condition: Contrast Induced Nephropathy
- Condition: Acute Kidney Injury
- Intervention (Drug): sodium bicarbonate
- Intervention (Drug): hypotone saline
- Lead sponsor: St. Antonius Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: St. Antonius Hospital (`cardio:org-st-antonius-hospital`)

## Provenance

Content hash: c432891d3c4fd9b40581fd44ac3330d059d3e0978a068e6f8681d61b5a30bfc5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
